RNA vaccine trial offers new hope for recurrent brain cancer patients
NCT ID NCT07492316
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This early-phase trial tests a personalized RNA vaccine for people with recurrent medulloblastoma, a type of brain tumor. The vaccine is made from the patient's own tumor material and aims to train the immune system to fight the cancer. The study includes up to 24 participants aged 3 to 39 and focuses on whether the vaccine can be made safely and reliably.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MEDULLOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UF Health Shands Children's Hospital
RECRUITINGGainesville, Florida, 32608, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted radiation zaps childhood brain tumors in early trial
- Targeted drug aims to shrink recurrent brain tumors by blocking key growth enzyme
- Parental distress may undermine treatment in children with recurrent brain tumors
- Experimental vaccine aims to rally immune system against recurrent brain cancer
- Targeted drug shows promise for kids with tough cancers
- New hope for kids with Hard-to-Treat cancers: targeted drug shows promise